Kevin Charles Gorman

Chief Executive Officer at Neurocrine Biosciences Inc.

Sits on 2 boards. Last updated September 28, 2026

Time on boards

Boards served
2
Current seats
2
Board service
7 years
Director since
2023

7 years of board service in total across 2 boards, counting each seat separately. Longest: Neurocrine Biosciences Inc., 3 years.

Neurocrine Biosciences Inc. Director · Chief Executive Officer
3 years · Since 2023
Xencor Inc. Director
3 years · Since 2023

Chief executive roles

Neurocrine Biosciences Inc. · Chief Executive Officer
Dates unknown

Shareholder support

Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Date Company Transaction Shares Price Value
Sep 11, 2026 Neurocrine Biosciences Inc. Grant or award +14,343 — —
Sep 11, 2026 Neurocrine Biosciences Inc. Shares withheld for tax −7,839 $156.22 $1,224,609
Jun 16, 2026 Xencor Inc. Grant or award +10,302 — —
Jun 15, 2026 Xencor Inc. Open-market sale −7,527 $12.31 $92,657
May 19, 2026 Neurocrine Biosciences Inc. Option exercise +205,088 $43.24 $8,868,005
May 19, 2026 Neurocrine Biosciences Inc. Open-market sale −245,088 $154.33 $37,824,431
Feb 13, 2026 Neurocrine Biosciences Inc. Option exercise +5,604 — —
Feb 13, 2026 Neurocrine Biosciences Inc. Shares withheld for tax −3,024 $124.12 $375,339
Feb 13, 2026 Neurocrine Biosciences Inc. Option exercise +5,377 — —
Feb 13, 2026 Neurocrine Biosciences Inc. Shares withheld for tax −2,901 $124.12 $360,072
Feb 13, 2026 Neurocrine Biosciences Inc. Grant or award +63,724 — —
Feb 13, 2026 Neurocrine Biosciences Inc. Shares withheld for tax −34,380 $124.12 $4,267,246
Jan 31, 2026 Neurocrine Biosciences Inc. Option exercise +5,142 — —
Jan 31, 2026 Neurocrine Biosciences Inc. Shares withheld for tax −2,845 $136.06 $387,091
Aug 7, 2025 Neurocrine Biosciences Inc. Option exercise +106,322 $35.99 $3,826,529

Questions about Kevin Charles Gorman

What boards is Kevin Charles Gorman on?

Kevin Charles Gorman sits on the boards of Neurocrine Biosciences Inc. and Xencor Inc.

What company is Kevin Charles Gorman the CEO of?

Kevin Charles Gorman is Chief Executive Officer of Neurocrine Biosciences Inc.

How long has Kevin Charles Gorman served on boards?

Our records show at least 7 years of board service across 2 boards, the earliest from 2023.

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.